Brazilian biotechnology startup BioLinker has successfully raised $1.7 million in a new funding round as it looks to significantly expand its operational capacities, scale up its synthetic biology infrastructure, and pioneer the integration of artificial intelligence into biological data generation. The recent capital injection marks a major milestone for the company, which specializes in the development and manufacturing of high-quality recombinant proteins for research, diagnostics, and diverse industrial applications.
The funding round was spearheaded by Axcell, a prominent investment firm that contributed $1.4 million to the biotechnology venture. Additional financial backing came from the São Paulo Research Foundation, known as FAPESP, which provided approximately $240,000 through its highly selective PIPE Phase 2 program. This latest financial boost underscores growing confidence from both private venture capital and public research funding bodies in Brazil’s burgeoning deep-tech and life sciences sectors.
Founded in 2018 by a team of visionary scientists and researchers from the University of São Paulo, BioLinker has steadily carved out a niche for itself at the intersection of synthetic biology and genetic engineering. The company’s core mission revolves around streamlining the production of recombinant proteins, which serve as foundational components for scientific research laboratories, clinical diagnostic kits, and industrial biotechnology processes. By leveraging advanced genetic engineering techniques, BioLinker provides local and international markets with reliable, high-grade biological materials that traditionally required complex and costly international supply chains.
With the fresh influx of capital from Axcell and FAPESP, BioLinker has set its sights on an ambitious expansion initiative centered in the heart of Brazil’s northern region. The startup plans to construct a cutting-edge, highly automated laboratory located within the Amazon BioBusiness Center in Manaus. This strategic positioning in Manaus is designed to harness the unique biodiversity and regional resources of the Amazon while establishing a world-class hub for technological innovation.
The upcoming facility will heavily utilize advanced robotics and automation to generate biological data at an unprecedented scale. According to the company’s strategic roadmap, this massive influx of biological data will be instrumental in training sophisticated artificial intelligence models. By marrying robotics, high-throughput biological data generation, and machine learning, BioLinker aims to accelerate DNA production capabilities within Brazil, positioning the nation as a competitive player in the global synthetic biology landscape.
In tandem with its physical and technological expansion in Manaus, BioLinker is also focusing on strengthening its internal human capital. The startup plans to double the size of its workforce, scaling its team from its current count of 12 employees up to 24 professionals. This expansion will encompass a wide range of specialized roles, including biotechnology engineers, software developers, robotic technicians, and research scientists, further fostering scientific talent and high-tech job creation within Brazil.
Despite securing a substantial $1.7 million in this latest financing push, BioLinker’s funding round remains actively open. The startup is currently in strategic discussions to bring an international investor on board to support its broader global expansion initiatives. This ongoing fundraising effort serves as a bridge toward a much larger Series A funding round, which the company anticipates launching within the next two years as it scales its operations to meet rising global demand.
Operating on a solid financial foundation, BioLinker already generates consistent, recurring revenue through its commercialized products and services. Management expects that the newly secured capital, when combined with existing revenue streams, will be sufficient to fully fund the company’s comprehensive business operations and strategic milestones for the next three years. This financial runway provides the startup with the stability needed to execute its long-term vision without immediate pressure, allowing the scientific and technical teams to focus entirely on research, automation, and the successful deployment of the Manaus laboratory facility.
